Logo image
An Investigation of Fibulin-2 in Hypertrophic Cardiomyopathy
Journal article   Peer reviewed

An Investigation of Fibulin-2 in Hypertrophic Cardiomyopathy

Ayman M. Ibrahim, Mohamed Roshdy, Sara Elshorbagy, Mohammed Hosny, Sarah Halawa, Dina Yehia, Hasnaa A. Elfawy, Ahmed Eldessouki, Faisal Mohamed, Amany Ellithy, …
International journal of molecular sciences, Vol.21(19), pp.7176-14
01/10/2020
PMID: 33003281

Abstract

Biochemistry & Molecular Biology Chemistry Chemistry, Multidisciplinary Life Sciences & Biomedicine Physical Sciences Science & Technology
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart muscle disease, with a prevalence of at least 1 in 500 in the general population. The disease is pleiotropic and is characterized by an increased stiffness of the myocardium, partly due to changes in the extracellular matrix (ECM), with elevated levels of interstitial fibrosis. Myocardial fibrosis is linked to impaired diastolic function and possibly phenotypic heterogeneity of HCM. The ECM consists of a very large number of proteins, which actively interact with each other as well as with myocardial cells. The role of other multiple components of the ECM in HCM has not been defined. Fibulin-2 is a glycoprotein component of the ECM, which plays an important role during embryogenesis of the heart; however, its role in adult myocardium has not been adequately studied. We here describe, for the first time, abnormal expression of fibulin-2 in the myocardium in patients with HCM as compared to normal controls. This abnormal expression was localized in the cytoplasm of myocardial cells and in the interstitial fibroblasts. In addition, fibulin-2 levels, measured by ELISA, were significantly elevated in the serum of patients with HCM as compared to normal controls.
url
https://doi.org/10.3390/ijms21197176View
Published (Version of record) Open

Metrics

Details

Logo image

Usage Policy